Top Markets
#1 Ontology Gas Ontology Gas +31.11%
#2 Verus Coin Verus Coin +22.50%
#3 Status Status +21.81%
#4 Bitway Bitway +15.86%
#5 ETHGas ETHGas +15.11%
#6 Geodnet Geodnet +14.89%
#7 The Black Bull The Black Bull +11.57%
#8 Derive Derive +11.47%
#9 Curve DAO Curve DAO +11.06%
#10 Fake World Assets Fake World Assets +10.89%
Coin of the day
Ontology Gas Ontology Gas
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Kedudukan dalam Saham #25521
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Harga Saham
$9.81
Disegerakkan terakhir: 2025-03-18
Modal Pasaran
$48.68M
Perubahan (1 hari)
1.55%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan AlloVir, Inc. (ALVR)

Kategori

Healthcare
Nisbah P/E bagi AlloVir, Inc. (ALVR)
Nisbah P/E pada August 2026 TTM: -2.02
Menurut laporan kewangan dan harga saham terkini AlloVir, Inc., nisbah P/E semasa (TTM) ialah -2.02. Pada akhir 2023, syarikat mempunyai nisbah P/E sebanyak 0.00.
Sejarah nisbah P/E bagi AlloVir, Inc. dari 2022 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) -2.02 158.95%
2024 -0.78 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -1,545.70%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -1,615.95%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -1,707.13%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 292.85%
US
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.